Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026 Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026